ITGAM and neoplasm: Although anti-CD11b mAb by itself had no effect on tumor progression, the strategy of MIS416 vaccination followed by anti-CD11b mAb significantly prolonged survival compared to vaccination followed by isotype (log-rank p = 0.0013) (Fig. 5a).